Table 2.
Baseline characteristics of the patient cohort
| Characteristics | Total cohort | Healthy control (HC) | Immune tolerant (IT) | HBeAg-positive active hepatitis (IA) | Inactive carrier (IC) | HBeAg-negative active hepatitis (ENEG) |
|---|---|---|---|---|---|---|
| Number of patients | 88 | 19 | 18 | 12 | 20 | 19 |
| Demography | ||||||
| Age, years (SE) | 35.26 (11.58) | - | 30.89 (1.77) | 31.75 (2.60) | 39.85 (3.02) | 37.68 (2.75) |
| Gender, n** | ||||||
| Female | 41 | 7 (17.1 %) | 13 (31.7 %) | 5 (12.2 %) | 14 (34.2 %) | 2 (4.9 %) |
| Male | 41 | 6 (14.6 %) | 5 (12.2 %) | 7 (17.1 %) | 6 (14.6 %) | 17 (41.5 %) |
| 7 missing | ||||||
| BMI, kg/m2 (SE) | 24.64 (6.40) | - | 25.93 (3.27) | 23.08 (1.12) | 24.41 (0.70) | 24.66 (0.79) |
| Race, n* | ||||||
| Asian | 44 (63.77 %) | - | 16 (36.4 %) | 9 (22.7 %) | 8 (18.21 %) | 10 (22.7 %) |
| Caucasian | 9 (13.04 %) | - | 0 (0.0 %) | 3 (33.3 %) | 2 (22.2 %) | 4 (44.4 %) |
| African | 8 (11.59 %) | - | 0 (0.0 %) | 0 (0.0 %) | 5 (62.5 %) | 3 (37.5 %) |
| Other | 8 (11.59 %) | - | 2 (25.0 %) | 0 (0.0 %) | 4 (50 %) | 2 (25.0 %) |
| Virology | ||||||
| Log HBV DNA, IU/ml (SE)*** | 5.55 (2.82) | - | 8.84 (0.07) | 7.40 (0.57) | 2.43 (0.15) | 4.39 (0.30) |
| HBV genotype A/B/C/D** | 13/16/20/20 | - | 0/8/8/2 | 3/2/6/1 | 6/5/2/6 | 4/1/3/11 |
| Chemistry/hematology | ||||||
| ALT, IU/l (SE)*** | 48.17 (43.56) | - | 24.50 (1.72) | 88.83 (16.93) | 23.90 (1.43) | 69.53 (10.91) |
BMI body mass index, SE standard error
Fisher’s exact p value: *p < 0.05, **p < 0.01
***ANOVA p value < 0.01